chapter
discuss
vaccin
militari
biodefens
research
personnel
well
vaccin
develop
uncommon
geograph
limit
diseas
militari
personnel
potenti
expos
mani
infecti
agent
endem
diseas
unnatur
form
biolog
weapon
increasingli
civilian
popul
may
target
terrorist
attack
use
microorgan
toxin
demonstr
purpos
dissemin
anthrax
spore
follow
ballist
attack
world
trade
center
pentagon
us
armi
longstand
program
develop
vaccin
combat
threat
within
us
depart
defens
dod
us
armi
medic
research
materiel
command
usamrmc
locat
fort
detrick
maryland
princip
organ
respons
vaccin
medic
countermeasur
biolog
warfar
agent
within
usamrmc
unit
direct
respons
defens
mission
us
armi
medic
research
institut
infecti
diseas
usamriid
also
fort
detrick
unit
state
maintain
offens
biolog
weapon
program
us
armi
medic
unit
within
walter
reed
armi
institut
research
washington
dc
serv
capac
mani
biowarfar
vaccin
current
avail
usamriid
elsewher
protect
laboratori
research
studi
agent
conceiv
us
armi
medic
unit
develop
close
nation
drug
laboratori
also
known
salk
institut
govern
servic
divis
tsigsd
vaccin
develop
fort
detrick
varieti
reason
remain
investig
new
drug
ind
howev
vaccin
undergon
extens
preclin
test
progress
phase
ii
trial
continu
mani
year
meanwhil
usamriid
research
other
continu
appli
new
technolog
develop
improv
vaccin
tabl
present
ind
vaccin
product
militari
interest
develop
usamrmcusamriid
vaccin
current
avail
administr
usamriid
special
immun
program
sip
one
vaccin
candid
junin
argentin
hemorrhag
fever
ahf
vaccin
shown
efficaci
phase
iii
trial
argentina
incorpor
countri
public
health
program
administ
thousand
individu
sever
vaccin
includ
venezuelan
equin
enceph
vee
eastern
equin
enceph
eee
vaccin
western
equin
enceph
wee
vaccin
tularemia
live
vaccin
strain
lv
rift
valley
fever
rvf
inactiv
vaccin
wholecel
q
fever
vaccin
also
administ
volunt
primarili
sip
contrast
chikungunya
chik
vaccin
strain
live
attenu
rvf
vaccin
q
fever
chloroformmethanol
residu
cmr
vaccin
vacciniahantaan
vaccin
administ
hundr
volunt
vaccin
activ
use
usamriid
sip
administ
approv
human
use
protocol
volunt
provid
written
inform
consent
vaccin
ind
vaccin
administ
voluntari
basi
atrisk
laboratori
field
worker
sip
particip
scientist
technician
usamriid
scientist
academia
feder
state
agenc
privat
drug
compani
also
particip
extramur
scientist
wish
receiv
one
vaccin
must
come
usamriid
vaccin
administr
safeti
monitor
protocol
consent
form
review
usamriid
scientif
review
committe
headquart
usamrmc
institut
review
board
offic
research
protect
within
usamrmc
headquart
fort
detrick
submiss
us
food
drug
administr
fda
protocol
conduct
accord
belmont
principl
dod
instruct
protect
human
subject
adher
ethic
standard
dodsupport
research
applic
dod
fda
regul
guidelin
mani
vaccin
use
sinc
subject
period
potenc
lotreleas
test
requir
fda
continu
monitor
safeti
immunogen
conduct
ind
vaccin
manag
author
us
armi
medic
materiel
develop
activ
nonclin
studi
divis
usamriid
fund
test
product
provid
medic
countermeasur
system
fort
belvoir
virginia
date
vaccin
demonstr
accept
safeti
profil
reason
immunogen
tabl
except
botulinum
toxoid
pentaval
abcd
vaccin
longer
administ
reactogen
product
live
attenu
vee
vaccin
frequent
induc
shortterm
system
reaction
inactiv
vaccin
except
wholecel
q
fever
vaccin
requir
multipl
dose
prime
frequent
period
boost
maintain
accept
level
neutral
antibodi
vaccin
administ
men
nonpregn
women
within
broad
rang
age
ethnic
race
except
junin
vaccin
efficaci
product
infer
absenc
laboratoryacquir
infect
among
recipi
howev
laboratori
practic
engin
control
evolv
concert
use
vaccin
quantifi
efficaci
continu
basi
difficult
usamriid
proactiv
evalu
shortterm
reactogen
also
longterm
medic
safeti
vaccin
vaccin
administ
atrisk
laboratori
worker
one
studi
aim
detect
longterm
medic
effect
repeat
inject
multipl
vaccin
second
studi
evalu
volunt
particip
biomed
research
part
oper
whitecoat
first
studi
consist
volunt
particip
multipl
immun
program
mip
cohort
commun
control
volunt
particip
mip
match
age
race
sex
major
studi
volunt
male
older
age
averag
age
year
studi
link
diseas
medic
condit
repetit
immun
multipl
antigen
singl
antigen
fatigu
note
myalgia
vomit
enceph
eg
vee
eee
wee
fever
rash
polyarthralgiasarthr
eg
chik
ross
river
viru
diseas
rrvd
formerli
call
epidem
polyarthr
onyongnyong
sever
excel
review
avail
classif
epidemiolog
clinic
featur
agent
although
dod
develop
vaccin
vee
viru
veev
wee
viru
weev
eee
viru
eeev
chik
viru
chikv
vaccin
remain
investig
ongo
research
seek
develop
improv
vaccin
pathogen
exampl
recent
studi
use
replicon
technolog
show
individu
replicon
vaccin
candid
vee
eee
combin
veev
weeveeev
replicon
particl
vaccin
elicit
strong
neutral
antibodi
protect
aerosol
challeng
veev
subtyp
iab
trinidad
donkey
strain
eeev
howev
individu
weev
replicon
combin
veevweeveeev
replicon
vaccin
elicit
low
level
neutral
antibodi
weev
confer
poor
protect
macaqu
particular
wolf
colleagu
argu
fdalicens
trival
veeweeee
vaccineon
overcom
safeti
immunogen
immun
interfer
issu
exist
ind
vaccinesi
requir
meet
requir
biodefens
commun
vaccin
also
would
great
valu
public
health
agricultur
commun
experi
sequenti
administr
alphaviru
vaccin
usamriid
led
number
interest
observ
relat
immunolog
interfer
prior
immun
inactiv
eee
andor
wee
vaccin
decreas
one
abil
mount
neutral
antibodi
respons
follow
receipt
live
attenu
vee
vaccin
howev
interfer
observ
order
administr
revers
vee
vaccin
given
first
similarli
interfer
occur
two
live
attenu
alphaviru
vaccin
vee
chik
vaccin
chik
administ
sequenti
volunt
initi
vaccin
vee
exhibit
poor
neutral
antibodi
respons
live
attenu
chik
vaccin
respons
rate
among
person
initi
inocul
chik
vaccin
placebo
receiv
live
attenu
vee
vaccin
geometr
mean
antibodi
titer
veev
measur
plaqu
reduct
neutral
test
prnt
uniformli
depress
chik
vaccin
recipi
compar
placebo
recipi
interfer
may
import
consider
develop
nextgener
alphaviru
vaccin
particularli
develop
multiag
alphaviru
vaccin
two
vee
vaccin
avail
human
use
ind
vaccin
live
attenu
product
formalininactiv
product
deriv
lineag
live
attenu
viru
subtyp
iab
strain
isol
donkey
brain
trinidad
passag
time
embryon
egg
viru
attenu
passag
fetal
guinea
pig
heart
fgph
cell
cultur
plaquepick
chick
embryo
fibroblast
cef
passag
four
addit
time
fgph
cell
cultur
vee
viru
design
direct
refer
passag
cell
cultur
vee
vaccin
formalininactiv
made
product
seed
undergon
one
addit
passag
cef
product
seed
passag
cef
deriv
vaccin
inactiv
formalin
freezedri
inactiv
procedur
base
use
salk
colleagu
inactiv
polioviru
contain
streptomycin
neomycin
concentr
commonli
among
subject
receiv
multipl
immun
find
associ
number
shot
number
antigen
time
mip
although
statist
signific
increas
decreas
sever
clinic
laboratori
test
observ
none
find
appear
clinic
signific
singl
import
find
studi
greater
frequenc
serum
monoclon
protein
observ
among
mip
subject
compar
control
subject
howev
associ
presenc
monoclon
protein
specif
diseas
medic
condit
seen
signific
implic
find
unclear
warrant
investig
larger
studi
volunt
particip
sip
complet
result
analyz
elucid
find
result
studi
expect
publish
second
studi
involv
men
enter
militari
servic
earli
day
cold
war
vietnam
war
express
conscienti
object
combat
men
offer
opportun
serv
medic
research
volunt
fort
detrick
biolog
warfar
defens
program
subject
particip
becam
known
oper
whitecoat
studi
assess
current
health
statu
oper
whitecoat
medic
research
volunt
serv
develop
joint
effort
dod
seventhday
adventist
church
mani
volunt
enrol
studi
expos
infecti
agent
vaccin
biolog
product
part
oper
whitecoat
studi
group
n
other
particip
research
studi
unexpos
control
subject
chose
particip
control
group
n
volunt
complet
selfadminist
questionnair
regard
health
statu
clinic
sign
symptom
reproduct
outcom
diseas
condit
diagnos
medic
provid
attempt
assess
frequenc
clinic
sign
symptom
diseas
individu
vaccin
individu
virul
agent
individu
antibiot
inert
substanc
exposur
yield
number
small
meaning
analysi
recipi
vee
vaccin
tularemia
vaccin
well
individu
expos
virul
coxiella
burnetii
among
exposur
possibl
associ
develop
asthma
receipt
tularemia
vaccin
vee
vaccin
virul
c
burnetii
observ
vaccine
vs
control
subject
cohort
associ
receipt
tularemia
vaccin
greater
frequenc
chronic
headach
suggest
vaccine
vs
control
subject
report
headach
occasion
frequent
problem
oppos
never
rare
problem
howev
associ
reach
statist
signific
advers
impact
overal
health
oper
whitecoat
volunt
could
conclus
attribut
particip
research
studi
fort
detrick
loma
linda
univers
continu
intermitt
followup
studi
alphavirus
group
mosquitoborn
lipidenvelop
positivesens
singlestrand
rna
virus
belong
famili
togavirida
alphavirus
respons
two
distinct
clinic
syndrom
fever
chill
headach
replac
test
shown
reduc
infect
formalin
inactiv
gammairradi
exampl
inactiv
vaccin
candid
show
loss
neurovirul
intracerebr
inocul
suckl
balbc
mice
suggest
vaccin
complet
inactiv
elicit
robust
immun
respons
furthermor
protect
demonstr
vaccin
candid
subcutan
challeng
veev
iab
trinidad
donkey
strain
follow
two
dose
either
vaccin
recent
research
test
vaccin
candid
use
variou
adjuv
rout
administr
subcutan
aerosol
challeng
addit
technolog
evalu
product
vaccin
vee
exampl
sharma
colleagu
found
hydrophob
alkyl
compound
effect
inactiv
virul
veev
strain
result
inactiv
vaccin
candid
efficaci
protect
mice
virul
veev
challeng
efficaci
enhanc
use
adjuv
rossi
colleagu
develop
live
attenu
vaccin
use
encephalomyocard
viru
intern
ribosom
entri
site
ire
construct
inhibit
translat
viral
protein
mosquito
cell
thu
prevent
transmiss
natur
veev
vector
iresbas
vee
vaccin
fulli
protect
mice
macaqu
clinic
diseas
aerosol
challeng
virul
veev
dna
vaccin
also
develop
protect
efficaci
studi
shown
promis
mice
guinea
pig
one
dna
vaccin
candid
also
demonstr
protect
aerosol
challeng
wildtyp
veev
nonhuman
primat
candid
base
novel
approach
dna
vaccin
develop
infecti
dna
idna
protect
one
balbc
mous
challeng
studi
inactiv
wee
vaccin
tsigsd
use
fort
detrick
sinc
immun
atrisk
laboratori
personnel
wee
vaccin
lyophil
product
deriv
supernat
fluid
primari
cef
cell
cultur
infect
attenu
strain
weev
supernat
fluid
harvest
filter
viru
inactiv
formalin
final
product
lyophil
storag
vaccin
contain
neomycin
primari
end
point
use
measur
immunogen
wee
vaccin
prnt
titer
least
consid
indic
respons
analysi
data
volunt
receiv
ml
inactiv
tsigsd
vaccin
subcutan
day
subject
respond
prnt
titer
greater
wherea
subject
fail
achiev
neutral
antibodi
titer
initi
nonrespond
convert
respond
statu
singl
booster
kaplanmei
plot
show
regimen
consist
three
initi
dose
one
booster
induc
prnt
titer
least
last
year
initi
respond
local
system
advers
event
uncommon
vaccin
among
vaccine
receiv
three
initi
inject
wee
vaccin
report
local
system
reaction
pr
pittman
ph
gibb
tl
cannon
unpublish
data
instanc
occup
wee
document
among
laboratori
worker
develop
neutral
antibodi
follow
vaccin
wee
vaccin
continu
administ
part
phase
ii
clinic
trial
howev
efficaci
trial
conduct
laboratori
infect
epizoot
veev
strain
close
relat
parent
strain
essenti
elimin
sinc
introduct
vaccin
improv
person
protect
equip
usamriid
immunolog
peopl
risk
exposur
vee
receiv
singl
dose
live
attenu
vaccin
seroconvert
prnt
titer
receiv
singl
booster
need
base
titer
prnt
nonrespond
receiv
booster
respons
rate
alon
follow
singl
boost
combin
respons
rate
well
observ
femal
respond
tend
titer
similar
male
respond
frequenc
nonrespond
tend
higher
among
women
men
one
studi
initi
respons
rate
among
recipi
singl
dose
respect
women
men
natur
sex
differ
understood
approxim
person
receiv
live
attenu
sustain
advers
reaction
includ
headach
sore
throat
malais
fatigu
myalgia
arthralgia
chill
fevera
suit
symptom
similar
seen
follow
natur
veev
infect
less
sever
local
reaction
rate
less
inactiv
vaccin
local
reaction
rate
approxim
essenti
system
reaction
associ
administr
diabet
mellitu
abort
teratogenesi
associatedepidemiolog
andor
anim
studieswith
natur
wildtyp
veev
infect
pregnanc
test
prior
vaccin
becam
avail
three
case
spontan
abort
stillbirth
tempor
relat
administr
howev
veev
recov
cultur
tissu
either
case
though
report
fda
case
never
publish
case
report
sinc
advent
pregnanc
test
great
care
use
ensur
women
pregnant
administr
abund
caution
person
famili
histori
diabet
mellitu
consid
inelig
vaccin
despit
lack
evid
causal
associ
diabet
mellitu
veev
infect
vaccin
ideal
vee
vaccin
would
high
seroconvers
rate
low
reaction
rate
standard
reactogen
moder
respons
rate
measur
neutral
antibodi
addit
protect
adequ
distantli
relat
veev
subtyp
iab
variant
enzoot
veev
subtyp
ii
vi
final
manufactur
process
requir
manipul
infecti
viral
particl
biosafeti
level
contain
laboratori
newgener
live
attenu
vaccin
candid
use
twin
sitedirect
mutagenesi
fulllength
complementari
dna
clone
virul
viru
rna
two
delet
mutationsa
lethal
delet
cleavag
signal
site
suppressor
mutat
site
glycoproteinthat
prevent
revers
wildtyp
veev
vaccin
candid
also
limit
potenti
transmiss
mosquito
elicit
crossprotect
differ
viral
strain
show
promis
preclin
studi
elicit
develop
impress
neutral
antibodi
level
human
volunt
phase
clinic
trial
howev
vaccin
associ
high
frequenc
fever
flulik
symptom
thu
develop
discontinu
long
histori
frequent
advers
reaction
relat
live
attenu
vee
vaccin
manufactur
decid
inactiv
develop
inactiv
vaccin
use
prime
vaccin
would
chikungunya
viru
chikv
caus
acut
viral
syndrom
human
character
fever
rash
arthriti
peopl
especi
human
leukocyt
antigen
hla
may
develop
longterm
joint
involv
although
document
epidem
occur
sinc
late
centuri
viru
first
isol
tanzanian
epidem
epidem
ravag
indian
ocean
island
east
madagascarla
mauritiusseychel
mayott
million
peopl
affect
sinc
start
epidem
sinc
spread
caribbean
india
case
also
occur
person
unit
state
europ
elsewher
travel
caribbean
decemb
kendrick
colleagu
report
first
case
chik
origin
unit
state
florida
genom
sequenc
six
isol
indian
ocean
outbreak
suggest
strain
respons
outbreak
relat
east
african
isol
addit
evid
sequenc
data
suggest
chikv
strain
respons
indian
ocean
outbreak
evolv
cours
outbreak
sever
distinct
variant
one
mutat
may
allow
chikv
effici
transmit
abund
mosquito
speci
la
aed
albopictu
may
help
explain
note
robust
epidem
sever
attempt
made
variabl
success
develop
efficaci
inactiv
vaccin
use
chick
embryo
cell
cultur
suckl
mous
brain
african
green
monkey
kidney
live
attenu
vaccin
made
seed
african
green
monkey
kidney
vaccin
use
chikv
strain
origin
isol
infect
patient
chik
epidem
thailand
african
green
monkey
kidney
passag
chikv
strain
made
walter
reed
armi
institut
research
transfer
usamriid
passag
medic
research
council
mrc
cell
passag
cell
chikv
clone
select
vaccin
seed
strain
base
biomark
chikv
efficaci
challeng
model
suckl
mice
nonhuman
primat
random
doubleblind
placebocontrol
trial
chik
vaccin
document
seroconvers
rate
among
volunt
one
year
immun
vaccine
remain
seroposit
inject
site
system
symptom
includ
flulik
symptom
similar
vaccin
placebo
recipi
howev
vaccin
tempor
associ
arthralgia
vaccine
one
volunt
vaccin
group
develop
prurit
eczemalik
rash
inject
site
interfer
chik
vaccin
live
attenu
vee
vaccin
discuss
live
attenu
chik
vaccin
requir
addit
phase
ii
phase
iii
clinic
test
current
epidem
caribbean
indian
ocean
india
offer
uniqu
prospect
phase
iii
clinic
test
vaccin
addit
strategi
develop
safe
efficaci
vaccin
chik
pursu
includ
chimer
alphaviru
vaccin
candid
use
veev
attenu
vaccin
strain
natur
attenu
strain
eeev
sindbi
viru
backbon
structur
protein
gene
chikv
wang
colleagu
found
chimera
produc
robust
neutral
antibodi
respons
vaccin
mice
fulli
protect
diseas
viremia
chikv
challeng
one
dna
vaccin
candid
express
compon
chikv
envelop
glycoprotein
produc
neutral
antibodi
mice
macaqu
second
dna
vaccin
candid
use
plasmid
code
chikvcapsid
new
lot
wee
vaccin
western
equin
enceph
vaccin
inactiv
tsigsd
lot
found
safe
immunogen
recent
phase
clinic
trial
dr
robert
rivard
usamriid
person
commun
studi
wee
vaccin
administ
dose
subcutan
upper
outer
aspect
tricep
threedos
primari
seri
day
mandatori
boost
day
subject
classifi
respond
day
subject
titer
wane
accept
level
month
follow
month
boost
subject
develop
titer
remain
level
least
year
dnabas
vaccin
wee
shown
promis
challeng
model
mice
one
studi
evalu
dna
vaccin
express
structur
gene
weev
strain
mice
receiv
four
intraepiderm
dose
surviv
challeng
homolog
strain
surviv
challeng
fleme
strain
respect
studi
demonstr
murin
model
efficaci
dna
vaccin
express
capsid
envelop
protein
weev
challeng
model
two
studi
replicationdefect
human
adenoviru
use
vector
vaccin
deliveri
first
studi
vector
encod
administ
singl
dose
confer
protect
challeng
homolog
heterolog
weev
strain
second
studi
vector
encod
alon
design
adenoviru
ad
provid
total
protect
homolog
heterolog
strain
weev
mice
potenti
drawback
approach
human
widespread
preval
antibodi
adenoviru
eee
vaccin
tsigsd
lyophil
product
origin
primari
cef
cell
cultur
infect
attenu
strain
eeev
seed
eee
vaccin
passag
twice
adult
mice
twice
guinea
pig
passag
nine
time
embryon
egg
follow
three
passag
cef
supernat
fluid
harvest
filter
contain
neomycin
streptomycin
wv
weight
per
volum
human
serum
albumin
usp
us
pharmacopoeia
viru
inactiv
formalin
inactiv
complet
residu
formalin
neutral
treatment
sodium
bisulfit
final
product
lyophil
storag
among
volunt
receiv
twodos
primari
seri
eee
vaccin
administ
subcutan
respond
prnt
titer
greater
initi
nonrespond
subsequ
seroconvert
follow
receipt
eee
vaccin
booster
administ
intraderm
among
initi
respond
whose
titer
wane
time
respond
booster
dose
eee
vaccin
local
system
side
effect
infrequ
occur
less
vaccine
primari
vaccin
seri
first
booster
kaplanmei
plot
show
two
primari
dose
one
intraderm
booster
tsigsd
provid
satisfactori
neutral
antieeev
antibodi
initi
respond
year
among
recent
find
regard
nextgener
eee
vaccin
singl
subcutan
dose
eee
vaccin
candid
attenu
via
ire
protect
vaccin
mice
intraperiton
challeng
addit
eeev
replicon
combin
veevweeveeev
replicon
protect
macaqu
aerosol
challeng
appropri
climatolog
condit
howev
explos
epizoot
among
anim
epidem
human
occur
consider
morbid
mortal
recent
year
rvf
demonstr
abil
spread
northward
egypt
yemen
saudi
arabia
asian
contin
consequ
spread
anim
human
popul
potenti
devast
spread
west
nile
viru
wnv
demonstr
virus
bound
atlant
ocean
potenti
overcom
barrier
thu
develop
vaccin
countermeasur
rvf
viru
import
protect
human
anim
popul
africa
middl
east
us
militari
personnel
involv
campaign
region
livestock
peopl
unit
state
elsewher
us
armi
develop
two
vaccin
combat
threat
inactiv
rvf
vaccin
tsi
gsd
recent
live
attenu
product
rvf
tsigsd
entebb
strain
rvf
isol
mosquito
pool
bwamba
counti
uganda
sourc
inactiv
vaccin
viru
passag
time
adult
mice
follow
two
passag
fetal
rhesu
lung
frhl
cell
form
product
seed
although
origin
vaccin
produc
primari
african
green
monkey
kidney
cell
current
vaccin
lot
produc
frhl
cell
vaccin
inactiv
formalin
follow
verif
viral
inactiv
residu
formaldehyd
neutral
sodium
bisulfit
less
studi
immunogen
safeti
inactiv
rvf
vaccin
human
period
show
vaccin
safe
immunogen
threedos
primari
seri
one
booster
administ
particular
volunt
given
three
dose
tsigsd
subcutan
day
respond
prnt
titer
greater
threefourth
initi
nonrespond
develop
prnt
titer
greater
singl
booster
howev
approxim
recipi
inactiv
rvf
vaccin
requir
repeat
boost
individu
booster
typic
result
adequ
titer
wane
next
year
prompt
anoth
booster
pr
pittman
unpublish
data
isol
rvf
strain
recov
nonfat
human
case
occur
first
egyptian
epidem
use
deriv
live
attenu
rvf
vaccin
viru
passag
twice
suckl
mous
brain
frhl
cell
attenu
serial
altern
passag
human
lung
cell
cultur
cell
certifi
vaccin
use
previous
describ
method
presenc
absenc
result
rvf
vaccin
lyophil
product
origin
supernat
fluid
harvest
final
mutagenesi
passag
vaccin
undergon
extens
safeti
test
challeng
studi
sever
anim
speci
rodent
sheep
includ
pregnant
ewe
neonat
lamb
cattl
includ
uterovaccin
bovid
monkey
furthermor
miller
colleagu
show
rvf
vaccin
administ
sheep
result
longlast
immun
limit
potenti
transmit
mosquito
feed
vaccin
anim
rvf
undergon
clinic
evalu
human
volunt
usamriid
phase
random
doubleblind
doseescalationrouteseek
studi
healthi
nonpregn
subject
randomli
select
receiv
rvf
plaqueform
unit
pfu
subcutan
n
pfu
intramuscularli
n
pfu
intramuscularli
n
placebo
n
infrequ
minor
side
effect
seen
among
placebo
recipi
one
volunt
titer
log
direct
inject
mice
construct
induc
broad
cellular
immun
produc
antibodi
detect
enzymelink
immunosorb
assay
elisa
recogn
nativ
antigen
anoth
group
evalu
formalininactiv
vero
celladapt
vaccin
candid
prepar
use
strain
india
epidem
recent
promis
viruslik
particl
vlp
vaccin
contain
viral
envelop
elicit
high
titer
neutral
antibodi
nonhuman
primat
human
volunt
addit
singl
immun
measl
virusvector
chik
vaccin
candid
induc
high
chikv
antibodi
titer
protect
mice
lethal
chikv
challeng
rrvd
epidem
polyarthr
first
recogn
australia
ross
river
viru
rrv
caus
agent
first
isol
pool
mosquito
rrvd
essenti
limit
australia
fiji
surround
island
includ
american
samoa
cook
island
sever
thousand
case
occur
per
year
human
polyarthr
may
follow
fever
rash
lethargi
symptom
gener
resolv
month
us
marin
particip
oper
tandem
thrust
queensland
australia
infect
rate
rrvd
develop
nine
individu
vaccin
candid
deriv
viru
isol
human
case
classic
rrvd
use
cell
line
albopictu
candid
underw
four
serial
passag
human
fetal
lung
cell
follow
two
passag
vero
cell
cell
cultur
contain
penicillin
uml
streptomycin
viru
inactiv
use
binari
ethyleneimin
mice
vaccin
induc
neutral
antibodi
confer
protect
viremia
intraven
challeng
live
rrv
recent
vero
cellgrown
formalininactiv
benzonasedigest
digest
host
cell
dna
sucros
gradientpurifi
vaccin
candid
induc
neutral
antibodi
mice
immun
mice
guinea
pig
fail
develop
viremia
follow
intraven
challeng
prototyp
strain
rrv
phase
iii
dose
escal
studi
healthi
adult
vaccin
safe
immunogen
administ
three
immun
day
month
four
dose
level
without
aluminum
hydroxid
ad
adjuv
adjuv
dose
stimul
highest
immun
respons
group
recent
complet
phase
iii
studi
healthi
younger
adult
age
year
healthi
older
adult
age
older
vaccin
well
toler
neutral
antibodi
titer
achiev
younger
adult
older
adult
third
vaccin
potenti
antibodydepend
enhanc
diseas
describ
rrv
vitro
need
consid
develop
vaccin
rrv
rvf
mosquitoborn
infect
endem
subsaharan
africa
primarili
affect
rumin
anim
ml
myelin
basic
protein
recommend
regimen
product
hantavax
two
dose
elisa
unit
ml
given
month
apart
subcutan
intramuscular
rout
littl
publish
vaccin
manufactur
report
toler
good
although
allerg
reaction
occur
presum
result
mous
brain
antigen
serolog
respons
measur
indirect
fluoresc
seen
nearli
vaccine
neutral
antibodi
usual
absent
one
dose
measur
approxim
subject
second
dose
decreas
month
time
booster
recommend
although
placebocontrol
data
efficaci
vaccin
avail
similar
vaccin
made
north
korea
reportedli
show
efficaci
hantavax
effect
uncontrol
epidemiolog
studi
done
south
korea
yugoslavia
although
neutral
antibodi
respons
persist
stimul
booster
dose
casecontrol
studi
conduct
republ
korea
estim
efficaci
two
dose
three
dose
wide
confid
limit
vaccin
made
cell
cultur
hantaviru
seoul
viru
strain
licens
china
substrat
cell
cultur
golden
hamster
kidney
mongolian
gerbil
kidney
efficaci
bival
vaccin
reportedli
better
fewer
reaction
use
mous
brainderiv
vaccin
anoth
korean
compani
develop
hantaviru
vaccin
made
vero
cell
protect
challeng
anim
elicit
strong
respons
n
protein
viru
usamriid
advanc
technolog
fuel
develop
bioengin
hantaviru
vaccin
two
experiment
approach
includ
recombin
vacciniavector
hantaan
viru
vaccin
carri
envelop
nucleocapsid
gene
gene
insert
bacteri
plasmid
dna
vaccin
recombin
vacciniavector
hantaan
viru
vaccin
efficaci
hamster
infect
model
even
preexist
immun
vaccinia
viru
present
could
overcom
second
intramuscular
inject
vaccin
candid
doubleblind
placebocontrol
clinic
trial
involv
volunt
use
two
subcutan
inject
week
apart
show
volunt
neutral
antibodi
hantaan
viru
vaccinia
viru
detect
respect
wherea
neutral
antibodi
hantaan
viru
detect
vacciniaimmun
volunt
show
effect
prior
vectordirect
immun
vaccin
abandon
dna
plasmid
code
protein
protect
monkey
challeng
south
american
hantaviru
elicit
antibodi
exert
passiv
protect
hamster
boost
monkey
year
later
show
immunolog
memori
induc
alphaviru
replicon
baculovirusproduc
protein
chimer
hepat
b
vlp
studi
addit
hantaviru
vaccin
candid
boudreau
colleagu
report
phase
clinic
trial
evalu
hantaan
viru
puumala
viru
msegment
dna
vaccin
prevent
hfr
volunt
receiv
either
hantaan
dna
vaccin
n
puumala
dna
vaccin
n
vaccin
n
three
dose
contain
mg
gold
per
dose
administ
week
apart
provid
volunt
particlemedi
epiderm
deliveri
singl
vaccin
elicit
neutral
antibodi
hantaan
viru
puumala
viru
respect
vaccine
neutral
antibodi
one
plaqu
cell
cultur
six
vaccine
transient
lowtit
viremia
detect
amplif
six
volunt
group
receiv
pfu
intramuscularli
neutral
antibodi
measur
prnt
titer
well
rvfspecif
immunoglobulin
ig
igg
observ
vaccin
recipi
highest
peak
geometr
mean
antibodi
titer
observ
group
receiv
pfu
intramuscularli
overal
rvf
recipi
avail
test
remain
seroposit
prnt
year
follow
inocul
joint
program
univers
texa
medic
branch
usamriid
develop
rvf
vaccin
complet
studi
fund
nation
institut
allergi
infecti
diseas
involv
administr
singl
intramuscular
dose
rvf
vaccin
male
nonpregn
femal
subject
vaccin
safe
immunogen
vaccin
trial
total
subject
develop
neutral
antibodi
rvf
viru
determin
prnt
titer
result
suggest
vaccin
result
lowlevel
viremia
viru
detect
direct
plaqu
assay
howev
first
day
vaccin
nine
isol
recov
five
subject
use
amplif
blind
doubl
passag
vero
cell
singlenucleotid
polymorph
revers
observ
attenu
mutat
parent
viru
anoth
rvf
live
attenu
vaccin
candid
clone
vaccin
candid
plaquepurifi
clone
rvf
viru
contain
larg
delet
small
genom
segment
disrupt
biolog
function
nonstructur
protein
nss
clone
proven
highli
immunogen
mice
sheep
goat
although
demonstr
moder
immunogen
cattl
approach
develop
vaccin
rvf
viru
preclin
stage
includ
vaccin
base
viral
vector
dna
vaccin
molecular
adjuv
subunit
vaccin
base
purifi
protein
vaccin
base
singlecycl
replic
vaccin
mutant
hantavirus
caus
hemorrhag
fever
renal
syndrom
hfr
continu
signific
endem
diseas
threat
us
militari
forc
korean
peninsula
throughout
europ
least
distinct
viral
strain
hfrscaus
virus
distribut
worldwid
three
viral
protein
abl
induc
protect
two
surfac
glycoprotein
also
call
gn
gc
n
nucleocapsid
protein
neutral
antibodi
protect
although
tcell
respons
may
also
use
addit
hfr
hantavirus
respons
hantaviru
pulmonari
syndrom
hantaviru
caus
syndrom
southwest
unit
state
call
sin
nombr
viru
snv
human
becom
infect
hantavirus
via
inhal
aerosol
rodent
excreta
prototyp
hantaviru
hantaan
first
isol
korea
first
vaccin
also
develop
protect
hfr
inactiv
vaccin
strain
harvest
suckl
mous
brain
concentr
protamin
sulfat
precipit
centrifug
concentr
expos
formalin
inactiv
purifi
ultrafiltr
sucros
gradient
ultracentrifug
aluminum
hydroxid
ad
vaccin
adjuv
thimeros
preserv
gelatin
stabil
final
product
produc
rhein
biotech
reportedli
less
ng
sever
member
arenavirida
famili
segment
negativestrand
rna
virus
recogn
caus
agent
viral
hemorrhag
fever
syndrom
human
date
effort
develop
protect
immunogen
arenavirus
met
limit
success
first
success
vaccin
arenaviru
junin
viru
develop
collabor
govern
argentina
us
armi
effort
develop
vaccin
pathogen
arenavirus
result
number
promis
candid
none
progress
clinic
trial
junin
viru
caus
agent
ahf
endem
pampa
northcentr
argentina
human
becom
infect
junin
viru
inhal
infect
rodent
secret
excret
death
occur
untreat
patient
afflict
ahf
sever
decad
attempt
made
argentina
develop
efficaci
vaccin
ahf
result
inactiv
live
attenu
vaccin
candid
fail
variou
reason
product
develop
usamriid
candid
descend
prototyp
xj
strain
junin
viru
isol
guinea
pig
fatal
ahf
case
follow
anoth
passag
guinea
pig
viru
underw
newborn
mous
brain
passag
clone
passag
time
certifi
frhl
cell
candid
prove
effect
prevent
diseas
guinea
pig
rhesu
macaqu
lethal
junin
viru
challeng
phase
phase
ii
clinic
test
human
candid
safe
immunogen
volunt
develop
antibodi
junin
viru
although
lower
level
seen
mild
natur
infect
develop
junin
virusspecif
cellular
immun
respons
pivot
efficaci
studi
volunt
random
receiv
vaccin
random
receiv
placebo
trial
volunt
develop
ill
met
clinic
case
definit
ahf
receiv
placebo
receiv
vaccin
vaccin
efficaci
intenttotreat
analysi
confid
interv
p
argentina
nation
institut
human
viral
diseas
produc
junin
vaccin
also
call
candid
ahf
test
human
volunt
compar
safeti
immunogen
candid
vaccin
produc
unit
state
use
previou
studi
vaccin
compar
usproduc
vaccin
term
safeti
efficaci
sever
advers
event
relat
vaccin
result
studi
argentina
nation
regulatori
author
anmat
licens
local
produc
candid
vaccin
vaccin
candid
recommend
person
risk
occup
agricultur
laboratori
exposur
junin
viru
develop
vaccin
repres
success
collabor
usamriid
argentin
ministri
health
social
action
auspic
unit
nation
develop
programm
pan
american
health
organ
year
hundr
thousand
peopl
argentina
countri
inocul
excel
record
safeti
effect
anoth
import
arenaviru
lassa
viru
transmit
rodent
west
africa
recent
larg
virus
detect
volunt
receiv
combin
vaccin
attempt
increas
seroconvers
hooper
colleagu
conduct
phase
clinic
trial
two
dna
vaccin
deliv
intramuscular
electropor
similar
boudreau
studi
volunt
three
group
nine
individu
receiv
three
dose
day
apart
either
hantaan
dna
vaccin
puumala
dna
vaccin
mixtur
vaccin
dose
vaccin
contain
mg
dna
total
volum
ml
salin
combin
vaccin
contain
mg
dna
vaccin
neutral
antibodi
found
volunt
receiv
hantaan
puumala
dna
vaccin
respect
result
combin
vaccin
show
vaccine
develop
neutral
antibodi
puumala
viru
three
volunt
highest
antibodi
level
puumala
also
develop
neutral
antibodi
hantaan
seriou
advers
event
result
vaccin
note
either
studi
hooper
colleagu
also
found
dna
vaccin
encod
viru
envelop
glycoprotein
snv
and
viru
caus
hantaviru
pulmonari
syndrom
elicit
hightit
neutral
antibodi
anim
model
hamster
vaccin
three
dose
snv
dna
vaccin
fulli
protect
lethal
challeng
snv
panhantaviru
vaccin
use
and
viru
snv
hantaan
viru
puumala
viru
plasmid
elicit
neutral
antibodi
four
virus
spread
flaviviru
wnv
introduct
new
york
citi
across
unit
state
dramat
exampl
emerg
infect
wnv
arboviru
bird
often
lethal
transmit
multipl
mosquito
speci
although
incid
human
infect
recent
decreas
wnv
frequent
caus
febril
ill
complic
meningoenceph
infect
wnvax
formalininactiv
wnv
vaccin
deriv
strain
isol
new
york
citi
test
number
anim
model
vaccin
administ
intraperiton
two
dose
protect
mice
lethal
challeng
wnv
recent
muraki
colleagu
found
mice
passiv
immun
serum
wnvaximmun
mice
also
protect
lethal
wnv
infect
administ
macaqu
wnvax
elicit
neutral
antibodi
clinic
trial
vaccin
plan
sever
phase
phase
ii
clinic
trial
complet
wnv
vaccin
candid
chimerivax
west
nile
vaccin
candid
contain
yellow
fever
viru
backbon
express
premembran
envelop
protein
wnv
report
safe
induc
neutral
antibodi
phase
clinic
trial
phase
ii
clinic
trial
chimerivax
well
toler
vaccine
seroconvert
phase
clinic
trial
dna
vaccin
candid
elicit
neutral
antibodi
wnv
recombin
subunit
vaccin
candid
consist
envelop
protein
truncat
ctermin
end
contain
ntermin
amino
acid
nativ
wnv
protein
mix
adjuv
produc
antibodi
detect
elisa
neutral
antibodi
assay
challeng
experi
control
rhesu
macaqu
detect
viremia
least
day
challeng
wherea
none
vaccin
anim
show
viremia
phase
trial
assess
safeti
vaccin
recent
complet
secret
lymphokin
clear
intracellular
infect
provid
immunolog
memori
develop
q
fever
vaccin
c
burnetii
adapt
grow
chick
embryo
yolk
sac
earli
vaccin
made
formalin
inactiv
organ
produc
egg
vaccin
effect
human
includ
subject
experiment
challeng
also
occasion
result
sever
local
reaction
sometim
progress
abscess
format
eventu
shown
reaction
associ
preexist
immun
q
fever
accordingli
practic
screen
prospect
vaccine
adoptedus
serolog
q
fever
antibodi
observ
local
indur
inocul
skin
test
antigen
made
dilut
vaccin
advanc
coxiella
biolog
vaccinolog
led
new
gener
vaccin
exampl
evid
show
phase
q
fever
organ
analog
smooth
form
bacteria
protect
transit
phase
ii
rough
would
occur
organ
passag
mani
time
chick
embryo
therefor
q
fever
vaccin
base
phase
organ
addit
research
recogn
purif
remov
chicken
protein
lipid
isol
whole
inactiv
coxiella
extract
filtrat
centrifug
would
result
cleaner
less
reactogen
highli
immunogen
product
two
wholecel
vaccin
came
use
highrisk
subject
australian
vaccin
made
licens
commonwealth
serum
laboratori
vaccin
ind
made
test
us
armi
administ
singl
subcutan
inject
australian
vaccin
qvax
purifi
use
high
concentr
nacl
remov
nonprotect
antigen
us
armi
vaccin
wholecel
inactiv
qfever
vaccin
ndbr
ind
also
extract
nacl
subject
ethanolfreon
extract
final
purifi
cahpo
brushit
column
despit
purif
process
howev
skin
test
prospect
recipi
remain
necessari
prevent
seriou
reaction
person
experienc
prior
infect
wholecel
vaccin
undergon
consider
clinic
test
australia
placebocontrol
trial
open
trial
abattoir
worker
show
efficaci
approach
tabl
vaccin
program
fund
australian
govern
incid
q
fever
australia
declin
us
armi
vaccin
subject
control
challeng
volunt
trial
also
prove
highli
success
two
metaanalys
found
qvax
respect
effect
data
consid
moder
qualiti
q
fever
outbreak
appar
caus
dairi
goat
occur
netherland
affect
individu
control
measur
includ
qvax
vaccin
individu
high
risk
develop
chronic
q
fever
epidem
sever
candid
vaccin
shown
protect
nonhuman
primat
model
includ
reassort
vesicular
stomat
virusvector
recombin
alphaviru
replicon
middl
east
respiratori
syndrom
mer
viruslik
sever
acut
respiratori
syndrom
sar
viru
spread
china
caus
worldwid
outbreak
coronaviru
reservoir
mer
camel
particularli
young
anim
acquir
respiratori
ill
transmit
human
addit
humantohuman
transmiss
repeatedli
observ
saudi
arabia
south
korea
coronavirus
possess
glycoprotein
spike
induc
neutral
antibodi
monoclon
antibodi
vaccin
base
spike
shown
good
protect
experiment
challeng
model
includ
macaqu
develop
vaccin
camel
human
proceed
novavax
develop
nanoparticl
consist
mer
spike
protein
togeth
iscomatrix
adjuv
shown
induc
neutral
antibodi
mice
german
worker
use
mva
vaccinia
viru
vector
mer
spike
protein
induc
neutral
antibodi
protect
mous
challeng
model
vaccin
research
center
nation
institut
health
develop
plasmid
recombin
protein
repres
fulllength
mer
spike
domain
spike
antigen
administ
mice
macaqu
neutral
antibodi
induc
anim
protect
challeng
viru
develop
candid
vaccin
depend
epidemiolog
market
size
q
fever
highli
infecti
zoonot
diseas
human
usual
caus
aerosol
transmiss
c
burnetii
infect
sheep
goat
organ
thought
rickettsia
consid
relat
legionella
bacteria
fever
pneumonia
frequent
clinic
manifest
q
fever
although
hepat
endocard
varieti
complic
may
develop
antibiot
effect
may
act
slowli
chronic
fatigu
syndrom
q
fever
report
presum
result
cytokin
dysregul
mechan
immun
q
fever
complex
although
antibodi
import
clear
extracellular
organ
sensit
tcell
lymphocyt
q
fever
antigen
leng
protect
subsequ
found
result
cellmedi
immun
passiv
transfer
spleen
cell
immun
mice
provid
protect
nonimmun
recipi
similar
immun
studi
done
monkey
also
demonstr
signific
immun
respons
vaccin
lv
lv
initi
given
scarif
volunt
fort
detrick
vaccin
procedur
advers
event
vaccin
evalu
subject
pink
scar
remain
month
vaccin
transient
axillari
lymphaden
observ
approxim
half
subject
none
men
exhibit
fever
system
reaction
follow
immun
lv
person
show
bacteri
agglutinin
antibodi
peak
titer
observ
day
vaccin
sustain
challeng
dose
organ
signific
protect
effect
seen
volunt
vaccin
lv
vaccin
person
show
clinic
ill
compar
unvaccin
control
subject
none
vaccin
person
develop
symptom
sever
enough
requir
treatment
higher
challeng
dose
howev
immun
overcom
challeng
organ
vaccin
person
show
symptomatolog
compar
control
subject
howev
lv
modul
ill
sever
vaccin
volunt
symptom
sever
enough
requir
treatment
compar
control
group
efficaci
live
tularemia
vaccin
administ
aerosol
also
evalu
one
studi
aerosol
vaccin
lv
protect
subject
challeng
virul
strain
f
tularensi
protect
subject
measur
circul
antibodi
one
subject
develop
diseas
circul
antibodi
lv
also
refer
ndbr
use
sinc
associ
signific
declin
rate
laboratoryacquir
infect
fort
detrick
absenc
firm
knowledg
concern
attenu
mutat
lv
residu
virul
vaccin
remain
investig
administ
protocol
written
inform
consent
lot
undergo
lotreleas
potenc
test
requir
fda
ind
product
effort
underway
develop
newgener
vaccin
tularemia
use
modern
technolog
lipopolysaccharid
f
tularensi
give
partial
protect
induct
antibodi
clearli
cellmedi
respons
antigen
necessari
optim
vaccin
highli
virul
strain
addit
aerosol
deliveri
may
give
better
protect
peripher
inocul
much
work
underway
creat
new
live
attenu
mutant
novel
subunit
vaccin
one
promis
approach
oxidantsensit
mutant
f
tularensi
lv
elicit
strong
humor
immun
respons
mice
without
caus
advers
effect
mice
vaccin
singl
intranas
dose
mutant
f
tularensi
lv
protect
lethal
respiratori
lv
challeng
vaccin
also
provid
partial
protect
lethal
challeng
virul
f
tularensi
strain
primarili
diseas
anim
brucellosi
first
describ
human
mediterranean
gastric
remitt
fever
malta
fever
consumpt
unpasteur
goat
milk
found
sourc
malta
epidem
effect
contain
outbreak
despit
limit
coverag
vaccin
campaign
elimin
problem
reaction
thirdgener
acellular
q
fever
vaccin
prepar
unit
state
former
czechoslovakia
vaccin
extract
chloroformmethanol
lipid
solvent
remov
lipid
thought
chief
offend
substanc
c
burnetii
yet
undergon
suffici
clinic
test
determin
whether
equival
wholecel
q
fever
vaccin
protect
human
addit
yet
clear
vaccin
overcom
problem
seriou
reaction
preexpos
individu
live
attenu
q
fever
vaccin
produc
chick
embryo
yolk
sac
develop
russia
safeti
question
vaccin
approach
investig
base
protein
antigen
dna
plasmid
code
variou
protein
better
q
fever
vaccin
need
induc
antibodi
thelper
type
cell
respons
yet
well
toler
individu
preexist
immun
elucid
key
protect
antigen
requir
tularemia
tularemia
bacteri
bioterror
threat
signific
endem
epidem
human
diseas
caus
bacterium
tularemia
francisella
tularensi
isol
edward
franci
made
associ
human
diseas
known
deer
fli
fever
andersson
colleagu
describ
transcript
respons
peripher
blood
follow
ulceroglandular
tularemia
human
author
identifi
seven
gene
whose
chang
express
predict
earli
phase
tularemia
addit
identifi
host
defens
develop
turn
f
tularensi
invas
data
import
identifi
potenti
diagnost
marker
tularemia
infect
mani
case
f
tularensi
document
american
medic
literatur
result
laboratori
exposur
occur
laboratori
personnel
receiv
one
inject
phenolkil
vaccin
andor
acetoneprepar
vaccin
one
earli
inactiv
product
foshay
vaccin
show
incomplet
protect
efficaci
tularemia
organ
introduc
respiratori
intracutan
rout
although
circul
antibodi
could
demonstr
follow
administr
vaccin
antibodi
gener
protect
conclud
protect
antigen
f
tularensi
destroy
inactiv
procedur
use
prepar
vaccin
although
antibodi
alon
consid
insuffici
partli
result
experi
kill
vaccin
effort
develop
live
vaccin
f
tularensi
undertaken
avoid
destruct
protect
antigen
live
vaccin
caus
actual
infect
thought
produc
immun
closer
caus
diseas
particular
gener
persist
antibodi
cellular
immun
requir
protect
diseas
soviet
investig
initi
develop
live
tularemia
vaccin
ampoul
viabl
tularemia
vaccin
brought
unit
state
russian
institut
epidemiolog
microbiolog
gamaleia
institut
shope
ampoul
product
eigelsbach
down
deriv
vaccin
strain
design
lv
studi
done
fort
detrick
earli
show
lv
protect
mice
guinea
pig
chalcharid
p
aeruginosa
conjug
keyhol
limpet
hemocyanin
found
elicit
opsonophagocyt
antibodi
mice
attenu
salmonella
vector
express
antigen
p
aeruginosa
lipopolysaccharid
given
intranas
protect
mice
challeng
interestingli
respons
case
mucos
bacteria
may
necessari
protect
mucos
rout
administr
may
improv
efficaci
virul
factor
algin
produc
mucoid
form
p
aeruginosa
one
strategi
pseudomona
vaccin
develop
rais
opson
antibodi
algin
one
group
conjug
algin
outer
membran
vesicl
n
meningitid
immun
mice
conjug
provid
protect
intranas
challeng
p
aeruginosa
thu
valid
concept
helicobact
pylori
colon
stomach
earli
life
exert
effect
adult
caus
gastriti
peptic
ulcer
lowgrad
gastric
lymphoma
mechan
diseas
involv
stimul
regulatori
possibl
cell
antibodi
cellular
mechan
seem
involv
protect
demonstr
anim
model
clinic
trial
test
ureas
secret
h
pylori
caga
pathogen
island
vaca
cytotoxin
neutrophilactiv
protein
result
past
promis
recent
howev
aluminumadjuv
combin
latter
three
antigen
stimul
strong
antibodi
cellular
respons
volunt
undergo
clinic
develop
approach
vlp
epitopebas
vaccin
alkyl
hydroperoxid
reductas
mannosyl
ahpc
thiolperoxidas
shown
promis
singleand
multicompon
vaccin
studi
use
murin
model
botul
neurolog
intox
caus
botulinum
neurotoxin
poison
agent
known
produc
bacterium
clostridium
botulinum
seven
toxin
type
g
recogn
g
caus
human
diseas
botulinum
neurotoxin
signific
biowarfar
bioterror
threat
neurotoxin
bind
presynapt
membran
prevent
acetylcholin
releas
result
symmetr
descend
flaccid
paralysi
classic
bulbar
palsi
character
diplopia
dysphonia
dysarthria
dysphagia
paralysi
progress
gener
weak
occur
untreat
death
occur
airway
obstruct
diaphragmat
muscl
paralysi
interestingli
toxin
mani
therapeut
use
wellnot
limit
treatment
blepharospasm
strabismu
cervic
torticolli
variou
dystonia
pentaval
abcd
botulinum
toxoid
pbt
avail
prophylact
countermeasur
botul
novemb
center
diseas
control
prevent
stop
provid
vaccin
ind
reduc
potenc
increas
reactogen
although
old
methodolog
produc
toxoid
ie
method
use
produc
pbt
improv
reduc
formalin
concentr
increas
puriti
botulinum
protein
advanc
candid
recombin
nontox
protein
hc
subunit
toxin
type
b
immunogen
clinic
trial
proceed
develop
peptid
toxin
includ
light
chain
n
termin
heavi
chain
also
test
fig
nonrepl
bruce
isol
etiolog
agent
fatal
case
brucellosi
initi
name
micrococcu
melitensi
genu
later
name
discover
current
known
brucella
melitensi
brucella
speci
nonsporeform
gramneg
coccobacilli
exist
worldwid
sever
anim
speci
becom
infect
brucella
speci
human
becom
infect
contact
infect
anim
consum
unpasteur
infect
milk
dairi
product
work
organ
laboratori
condit
brucellosi
manifest
nonspecif
flulik
symptom
often
much
promin
gastrointestin
symptom
feasibl
infect
aerosol
make
brucella
possibl
agent
biowarfar
effect
vaccin
live
kill
avail
anim
use
vaccin
led
decreas
human
diseas
anim
infect
enzoot
nevertheless
estim
annual
human
case
still
occur
worldwid
live
vaccin
brucella
abortu
extens
use
russia
gave
protect
although
somewhat
reactogen
ongo
research
seek
attenu
live
vaccin
use
anim
develop
subunit
vaccin
base
membran
ribosom
protein
dna
plasmid
code
protein
exampl
protect
anim
achiev
outer
membran
protein
gene
pseudomona
aeruginosa
common
pathogen
ventil
patient
burn
howev
also
caus
lifethreaten
infect
peopl
cystic
fibrosi
owe
product
thick
mucoid
capsul
although
antibodi
lipopolysaccharid
develop
peopl
cystic
fibrosi
infect
low
affin
protect
contrast
artifici
immun
lipopolysaccharid
eight
differ
strain
coupl
chemic
pseudomona
exotoxin
elicit
highaffin
igg
antibodi
studi
cellular
immun
respons
show
induct
antigenspecif
lymphocyt
prolifer
cytokin
secret
period
peopl
cystic
fibrosi
immun
polysaccharid
conjug
toxin
fewer
pseudomona
infect
tendenc
toward
less
colon
mucoid
strain
herzog
c
person
commun
plotkin
novemb
importantli
lung
function
also
better
vaccine
phase
iii
trial
patient
cystic
fibrosi
receiv
four
dose
bival
p
aeruginosa
flagella
vaccin
significantli
less
like
one
acut
p
aeruginosa
infect
receiv
placebo
vs
among
vaccine
placebo
recipi
respect
howev
addit
antigen
expect
provid
better
protect
vaccin
contain
formalininactiv
whole
pseudomona
bacteria
administ
oral
healthi
volunt
without
advers
reaction
signific
serum
iga
respons
mani
experiment
vaccin
develop
includ
one
base
flagellar
antigen
outer
membran
protein
oprf
opri
exotoxin
exampl
one
dna
vaccin
encod
pseudomona
exotoxin
pcrv
shown
promis
mice
p
aeruginosa
hybrid
outer
membran
protein
oprei
vaccin
well
toler
immunogen
recent
random
placebocontrol
phase
studi
mucoid
exopolysactreat
vaccin
cdi
current
clinic
develop
sanofi
pasteur
pfizer
candid
c
difficil
toxoid
vaccin
compos
highli
purifi
formalin
genet
inactiv
toxoid
togeth
aluminum
adjuv
deliv
intramuscular
inject
earli
clinic
data
suggest
relationship
immun
respons
toxin
b
protect
primari
recurr
case
cdi
colon
system
anamnest
respons
toxin
evidenc
increas
serum
igg
antitoxin
level
associ
asymptomat
carriag
c
difficil
serum
igg
antitoxin
level
also
significantli
correl
igg
level
toxin
b
antigen
also
higher
asymptomat
carrier
patient
cdi
higher
igg
antibodi
toxin
associ
protect
recurr
initi
phase
studi
candid
vaccin
induc
igg
antibodi
toxin
b
resolut
recurr
diarrhea
recent
phase
ii
studi
sanofi
candid
given
high
dose
elicit
function
antibodi
respons
adult
elderli
volunt
least
day
without
safeti
issu
addit
work
begun
use
colon
factor
vaccin
antigen
includ
proteas
adhes
molecul
cell
wall
polysaccharid
conjug
diphtheria
toxoid
variant
crm
anoth
approach
vaccin
develop
baliban
colleagu
creat
synthet
dna
vaccin
encod
receptor
bind
domain
c
difficil
toxin
toxin
b
mice
nonhuman
primat
vaccin
demonstr
robust
immunogen
immun
mice
protect
challeng
c
difficil
spore
homolog
heterolog
strain
refer
chapter
avail
expertconsultcom
adenovirusvector
monoval
c
vaccin
given
intranas
oral
also
shown
induc
serum
secretori
antibodi
protect
anim
recombin
bival
vaccin
rbv
ab
complet
phase
ii
safeti
immunogen
test
human
inevit
new
vaccin
botul
licens
demonstr
efficaci
anim
although
titer
antibodi
correl
efficaci
known
human
studi
guinea
pig
suggest
low
level
u
protect
march
fda
approv
heptaval
equin
abcdefg
botul
antitoxin
treat
individu
symptom
botul
exposur
suspect
exposur
botulinum
neurotoxin
babybig
avail
california
treat
infant
botul
sinc
howev
vaccin
prophylact
protect
botul
current
avail
unit
state
clostridium
difficil
inhabit
human
gastrointestin
tract
certain
condit
produc
toxin
caus
diarrhea
precipit
caus
c
difficil
infect
cdi
seem
elimin
intestin
flora
antibiot
treatment
incid
diseas
increas
consider
recent
year
antibodi
toxin
produc
c
difficil
b
need
prevent
ill
much
work
progress
develop
use
monoclon
antibodi
toxin
prophylaxi
heavi
chain
light
chain
tsigsd
ind
